VenuGPillarisettyMD

Pancreas, Surgical Oncology (Other than Breast), Minimally Invasive Surgery

Professor, Surgery, University of Washington School of Medicine; Associate Medical Director of Surgical Oncology, Fred Hutch Cancer Center and University of Washington Medical Center

Join to view full profile

Dr. Pillarisetty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pillarisetty's full profile

Already have an account?

Office
1959 NE Pacific St
Box 356410
Seattle, WA 98195
Phone+1 206-616-4924

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2007 - 2009
UMass Chan Medical SchoolResidency, Surgery, 1999 - 2007
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999

Certifications & Licensure

WA State Medical License 2009 - 2026
ID State Medical License 2023 - 2025
American Board of Surgery Surgery

Awards, Honors, & Recognition

Top Doctors Seattle Metropolitan Magazine
Fellow American College of Surgeons

Clinical Trials

A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula Start of enrollment: 2018 Feb 20
Completed
Phase 2

Publications & Presentations

PubMed

109 citations
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Cristina P. Rodriguez, Qian Vicky Wu, Jenna M. Voutsinas, Jonathan R. Fromm, Xiuyun Jiang
Clinical Cancer Research. 2020-02-15
267 citations
Neuroendocrine tumors, version 1.2015
Matthew H. Kulke, Manisha H. Shah, Al B. Benson, Emily K. Bergsland, Jordan Berlin
Journal of the National Comprehensive Cancer Network. 2015-01-01
191 citations
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Tyrel T. Smith, Howell F. Moffett, Sirkka B. Stephan, Cary F. Opel, Amy Dumigan
The Journal of Clinical Investigation. 2017-06-01

Press Mentions

BBI Funds Immunotherapy Research to Help Address Pancreatic and Kidney Cancers, a Project That ‘Exemplifies Precision Medicine’April 12th, 2022
To Operate or Not? Navigating Gray Areas in Surgical OncologyJanuary 17th, 2020